Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | PKM | P14618 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | THPO | P40225 | 2/20 | 0.80 |
| ▸ | MTOR | P42345 | 2/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niclosamide SCHEMBL27365268 | 0.89 | KMT2A (1.00) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL67182 | 0.89 | KMT2A (1.00) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL29363878 | 0.89 | KMT2A (1.00) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL6662409 | 0.89 | KMT2A (1.00) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL28313524 | 0.89 | KMT2A (1.00) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL31098821 | 0.88 | KMT2A (0.97) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL2061202 | 0.88 | KMT2A (0.97) | LMNAMAPTPKMMAPK1MEN1 | |
| Niclosamide SCHEMBL27937315 | 0.88 | KMT2A (0.97) | LMNAMAPTPKMMAPK1MEN1 | |
| SCHEMBL29936061 | 0.88 | KCNMA1 (0.78) | LMNAMAPTPKMMAPK1MEN1 | |
| SCHEMBL4264455 | 0.88 | KCNMA1 (0.78) | LMNAMAPTPKMMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DUKE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3338783-B1 | ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES | UNION THERAPEUTICS AS (DK) | 2024-01-24 | — | — | EP | disclosed |
| US-20230190685-A1 | FORMULATION | UNION therapeutics A/S (DK) | 2023-06-22 | — | — | US | disclosed |
| US-20230147683-A1 | TREATMENT | UNION therapeutics A/S (DK) | 2023-05-11 | — | — | US | disclosed |
| CN-115701984-A | Treatment of | 联合治疗股份公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-115701983-A | Formulations | 联合治疗股份公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-4125805-A1 | FORMULATION | UNION therapeutics A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125804-A1 | TREATMENT | UNION therapeutics A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| US-11324708-B1 | Niclosamide formulations for treating disease | UNION therapeutics A/S (DK) | 2022-05-10 | — | — | US | disclosed |
| WO-2021198116-A1 | FORMULATION | UNION therapeutics A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198115-A1 | TREATMENT | UNION therapeutics A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| US-11045434-B1 | Niclosamide formulations for treating disease | UNION therapeutics A/S (DK) | 2021-06-29 | — | — | US | disclosed |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| WO-2020028392-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-3010511-B1 | ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES | ANTIBIOTX AS (DK) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045434-B1 | Niclosamide formulations for treating disease | ACE2, ACE, RYR2 | LMNA 3387/4885MAPT 478/4885PKM 4642/4885 |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DNER, SFRP1, WNT1 | LMNA 4067/4885MAPT 2811/4885PKM 4566/4885 |
| US-11324708-B1 | Niclosamide formulations for treating disease | ACE2, ACE, RYR2 | LMNA 3387/4885MAPT 478/4885PKM 4642/4885 |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DNER, SFRP1, WNT1 | LMNA 4067/4885MAPT 2811/4885PKM 4566/4885 |
| US-20230190685-A1 | FORMULATION | NOD2, SCLY, SFXN3 | LMNA 4370/4885MAPT 1093/4885PKM 4381/4885 |
| US-20230147683-A1 | TREATMENT | MME, NCSTN, NAPEPLD | LMNA 3105/4885MAPT 310/4885PKM 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.